Expertise in
13
conditions

Dr. Nebu V. Koshy

Oncology | Hematology
3410 Worth Street, Suite 300, 
Dallas, TX 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
13
conditions
3410 Worth Street, Suite 300, 
Dallas, TX 

Overview

Nebu Koshy is an Oncologist and a Hematologist practicing medicine in Dallas, Texas.

Dr. Koshy is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Aplastic Anemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Dr. Koshy is board certified in Medical Oncology- American Board Of Internal Medicine, Hematology- American Board Of Internal Med/Hematology, Medical Oncology- American Board Of Internal Med/Medical Oncology, and Hematology- American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 16 peer reviewed articles and participating in 3 clinical trials. Dr. Koshy is currently accepting new patients.

Specialties

Oncology
Hematology

Licenses

Internal Medicine in LA

Board Certifications

Medical Oncology- American Board Of Internal Medicine
Hematology- American Board Of Internal Med/Hematology
Medical Oncology- American Board Of Internal Med/Medical Oncology
Hematology- American Board Of Internal Medicine

Fellowships

Hematology/Oncology, Louisiana State University In Shreveport - 2010
Hematology/Oncology, LA State Univ at Shreveport School of Medicine - 2010
Bone Marrow/Stem Cell Transplant, Weill Medical College of Cornell University - 2015
Bone Marrow and Stem Cell Transplant, Weill Cornell Medicine - 2015

Hospital Affiliations

Baylor Scott & White Heart & Vascular Hospital - Dallas
Baylor University Medical Center
Baylor Scott & White The Heart Hospital - Dallas
Baylor Scott & White Institute For Rehabilitation - Dallas
Baylor Scott & White The Heart Hospital - Plano
Baylor Scott & White The Heart Hospital - Denton
Baylor University Medical Center, Part Of Baylor Scott & White Health

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Texas Oncology, P.A.
3410 Worth Street, Suite 300, Dallas, TX 75246

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

16 Total Publications

Surveillance Strategies in Follicular Non-Hodgkin's Lymphoma's Using Molecular and Genetic Markers Improve Cost-efficiencies Over Routine Imaging Studies.
Surveillance Strategies in Follicular Non-Hodgkin's Lymphoma's Using Molecular and Genetic Markers Improve Cost-efficiencies Over Routine Imaging Studies.
Journal: American journal of clinical oncology
Published: October 26, 2025
Similar Doctors
Expertise in
38
conditions
Dr. Farrukh T. Awan
Hematology | Oncology
Expertise in
38
conditions
Dr. Farrukh T. Awan
Hematology | Oncology
Referral may be required

UT Southwestern-Bill And Rita Clements Advanced Medical Imaging Center

2201 Inwood Rd, 
Dallas, TX 
 (4.3 miles away)
214-645-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Farrukh Awan is a Hematologist and an Oncologist practicing medicine in Dallas, Texas. Dr. Awan is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
33
conditions
Dr. Daniel C. Bowers
Hematology | Oncology
Expertise in
33
conditions
Dr. Daniel C. Bowers
Hematology | Oncology
Referral may be required

Children's Medical Center/Children's Health

1935 Medical District Dr, 
Dallas, TX 
 (3.7 miles away)
214-456-2382
Languages Spoken:
English
See accepted insurances

Daniel Bowers is a Hematologist and an Oncologist practicing medicine in Dallas, Texas. Dr. Bowers is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Ependymoma, Posterior Fossa Tumor, Medulloblastoma, and Brain Tumor.

Expertise in
11
conditions
Dr. Naomi J. Winick
Hematology | Oncology
Expertise in
11
conditions
Dr. Naomi J. Winick
Hematology | Oncology
Referral may be required

Children's Medical Center/Children's Health

1935 Medical District Dr, 
Dallas, TX 
 (3.7 miles away)
214-648-3896
Languages Spoken:
English
See accepted insurances

Naomi Winick is a Hematologist and an Oncologist practicing medicine in Dallas, Texas. Dr. Winick is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Febrile Neutropenia, Childhood Acute Myeloid Leukemia, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Nebu V. Koshy

How do I make an appointment with Dr. Nebu V. Koshy?

You can book an appointment with Dr. Nebu V. Koshy by calling their office at 214-370-1500. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Nebu V. Koshy a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Nebu V. Koshy is classified as an Distinguished expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Nebu V. Koshy specialize in?

While Dr. Nebu V. Koshy is a Oncology, they have specific expertise in Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), and Aplastic Anemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Nebu V. Koshy participate in research or clinical trials?

Yes. Dr. Nebu V. Koshy has published 16 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Nebu V. Koshy's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Nebu V. Koshy accept my insurance?

Dr. Nebu V. Koshy accepts most major insurance plans, including Aetna and Baylor Scott & White Health. We recommend calling the office directly at 214-370-1500 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Koshy's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 42 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile